{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T15:59:13Z","timestamp":1793721553008,"version":"4.6.1"},"reference-count":88,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.neurol.2024.09.006","type":"journal-article","created":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T11:54:36Z","timestamp":1728302076000},"page":"971-981","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["New treatment strategies in Myasthenia gravis"],"prefix":"10.1016","volume":"180","author":[{"given":"S.","family":"Attarian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2024.09.006_bib0445","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/mus.27832","article-title":"Myasthenic crisis","volume":"68","author":"Claytor","year":"2023","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.neurol.2024.09.006_bib0450","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.neurol.2024.09.006_bib0455","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1172\/JCI114724","article-title":"HLA antigens in Japanese patients with myasthenia gravis","volume":"86","author":"Matsuki","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1016\/j.neurol.2024.09.006_bib0460","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/0140-6736(92)92343-E","article-title":"Distortion of HLA gene transmission in childhood-onset myasthenia gravis","volume":"340","author":"Matsuki","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2024.09.006_bib0465","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2024.09.006_bib0470","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/nyas.13518","article-title":"Myasthenia gravis with antibodies to MuSK: an update","volume":"1412","author":"Evoli","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.neurol.2024.09.006_bib0475","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","article-title":"A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis","volume":"52","author":"Zisimopoulou","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1016\/j.neurol.2024.09.006_bib0480","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: Executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.09.006_bib0485","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International Consensus Guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.09.006_bib0490","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1136\/ard.2008.092163","article-title":"Dose-related patterns of glucocorticoid-induced side effects","volume":"68","author":"Huscher","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.neurol.2024.09.006_bib0495","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0733-8619(05)70373-X","article-title":"Side effects of immunosuppressant therapies used in neurology","volume":"16","author":"Machkhas","year":"1998","journal-title":"Neurol Clin"},{"key":"10.1016\/j.neurol.2024.09.006_bib0500","doi-asserted-by":"crossref","first-page":"102712","DOI":"10.1016\/j.autrev.2020.102712","article-title":"Update in immunosuppressive therapy of myasthenia gravis","volume":"20","author":"Lascano","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.neurol.2024.09.006_bib0505","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1111\/ene.14730","article-title":"Cancer in myasthenia gravis subtypes in relation to immunosuppressive treatment and acetylcholine receptor antibodies: A Swedish nationwide register study","volume":"28","author":"Verwijst","year":"2021","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurol.2024.09.006_bib0510","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13023-023-02727-0","article-title":"Physician- and patient-reported perspectives on myasthenia gravis in Europe: a real-world survey","volume":"18","author":"Mahic","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.neurol.2024.09.006_bib0515","first-page":"97","article-title":"Patient-reported symptom severity in a nationwide myasthenia gravis cohort: cross-sectional analysis of the Swedish GEMG Study","author":"Petersson","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.09.006_bib0520","first-page":"255","article-title":"Clinical characteristics of refractory myasthenia gravis patients","volume":"86","author":"Suh","year":"2013","journal-title":"Yale J Biol Med"},{"key":"10.1016\/j.neurol.2024.09.006_bib0525","doi-asserted-by":"crossref","DOI":"10.1177\/1756285617749134","article-title":"When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies","volume":"11","author":"Mantegazza","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.neurol.2024.09.006_bib0530","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1111\/ene.14675","article-title":"Performance of different criteria for refractory myasthenia gravis","volume":"28","author":"Tran","year":"2021","journal-title":"Euro J Neurol"},{"key":"10.1016\/j.neurol.2024.09.006_bib0535","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41582-023-00916-w","article-title":"Myasthenia gravis: the changing treatment landscape in the era of molecular therapies","volume":"20","author":"Iorio","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurol.2024.09.006_bib0540","doi-asserted-by":"crossref","first-page":"e16180","DOI":"10.1111\/ene.16180","article-title":"Refocusing generalized myasthenia gravis: patient burden, disease profiles, and the role of evolving therapy","volume":"31","author":"Sacc\u00e0","year":"2024","journal-title":"Euro J Neurol"},{"key":"10.1016\/j.neurol.2024.09.006_bib0545","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1080\/14656566.2024.2332610","article-title":"Promising therapies for the treatment of myasthenia gravis","volume":"25","author":"Uysal","year":"2024","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1016\/j.neurol.2024.09.006_bib0550","doi-asserted-by":"crossref","first-page":"1370411","DOI":"10.3389\/fphar.2024.1370411","article-title":"Advancements and prospects of novel biologicals for myasthenia gravis: toward personalized treatment based on autoantibody specificities","volume":"15","author":"Ma","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.neurol.2024.09.006_bib0555","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.neurol.2024.09.006_bib0560","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/bs.ai.2015.12.006","article-title":"Adoptive T-cell therapy for cancer","volume":"130","author":"Yang","year":"2016","journal-title":"Adv Immunol"},{"key":"10.1016\/j.neurol.2024.09.006_bib0565","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.autrev.2013.03.001","article-title":"Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4","volume":"12","author":"Verschuuren","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.neurol.2024.09.006_bib0570","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3389\/fimmu.2020.00776","article-title":"Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology","volume":"11","author":"Fichtner","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurol.2024.09.006_bib0575","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1172\/JCI29894","article-title":"Myasthenia gravis: past, present, and future","volume":"116","author":"Conti-Fine","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.neurol.2024.09.006_bib0580","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/00005072-197803000-00008","article-title":"Ultrastructural localization of immune complexes (IgG and C3) at the end-plate in experimental autoimmune myasthenia gravis","volume":"37","author":"Sahashi","year":"1978","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.neurol.2024.09.006_bib0585","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1212\/WNL.29.2.179","article-title":"Passively transferred experimental autoimmune myasthenia gravis. Sequential and quantitative study of the motor end-plate fine structure and ultrastructural localization of immune complexes (IgG and C3), and of the acetylcholine receptor","volume":"29","author":"Engel","year":"1979","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.09.006_bib0590","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0092-8674(00)81251-9","article-title":"The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo","volume":"85","author":"DeChiara","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.neurol.2024.09.006_bib0595","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1007\/s00018-012-1209-9","article-title":"Structural mechanisms of the agrin-LRP4-MuSK signaling pathway in neuromuscular junction differentiation","volume":"70","author":"Zong","year":"2013","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.neurol.2024.09.006_bib0600","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009167","article-title":"The role of MuSK in synapse formation and neuromuscular disease","volume":"5","author":"Burden","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.neurol.2024.09.006_bib0605","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3389\/fimmu.2020.00613","article-title":"Long-lasting rituximab-induced reduction of specific\u00a0\u2014\u00a0but not total\u00a0\u2014\u00a0IgG4 in MuSK-positive myasthenia gravis","volume":"11","author":"Marino","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurol.2024.09.006_bib0610","doi-asserted-by":"crossref","first-page":"948259","DOI":"10.3389\/fimmu.2022.948259","article-title":"Aire and Fezf2, two regulators in medullary thymic epithelial cells, control autoimmune diseases by regulating TSAs: Partner or complementer?","volume":"13","author":"Qi","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurol.2024.09.006_bib0615","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.4049\/jimmunol.167.4.1935","article-title":"Somatic hypermutation and selection of B cells in thymic germinal centers responding to acetylcholine receptor in myasthenia gravis","volume":"167","author":"Sims","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.neurol.2024.09.006_bib0620","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/ana.23691","article-title":"Risk for myasthenia gravis maps to a (151) Pro\u2192Ala change in TNIP1 and to human leukocyte antigen-B*08","volume":"72","author":"Gregersen","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2024.09.006_bib0625","doi-asserted-by":"crossref","first-page":"605902","DOI":"10.3389\/fneur.2020.605902","article-title":"Controversies in ocular myasthenia gravis","volume":"11","author":"Evoli","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurol.2024.09.006_bib0630","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/s41582-023-00825-y","article-title":"Advances in the therapeutic algorithm for myasthenia gravis","volume":"19","author":"Dalakas","year":"2023","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurol.2024.09.006_bib0635","doi-asserted-by":"crossref","DOI":"10.1177\/17562864231213240","article-title":"Guideline for the management of myasthenic syndromes","volume":"16","author":"Wiendl","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.neurol.2024.09.006_bib0640","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/CND.0000000000000377","article-title":"Current and upcoming treatment modalities in myasthenia gravis","volume":"23","author":"Beladakere Ramaswamy","year":"2021","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1016\/j.neurol.2024.09.006_bib0645","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ncl.2018.01.011","article-title":"Treatment of myasthenia gravis","volume":"36","author":"Farmakidis","year":"2018","journal-title":"Neurol Clin"},{"key":"10.1016\/j.neurol.2024.09.006_bib0650","first-page":"1767","article-title":"Myasthenia gravis and congenital myasthenic syndromes","volume":"25","author":"Ciafaloni","year":"2019","journal-title":"Continuum (Minneap Minn)"},{"key":"10.1016\/j.neurol.2024.09.006_bib0655","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/ncpneuro0810","article-title":"Steroids and immunosuppressant drugs in myasthenia gravis","volume":"4","author":"Sathasivam","year":"2008","journal-title":"Nat Clin Pract Neurol"},{"key":"10.1016\/j.neurol.2024.09.006_bib0660","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1056\/NEJMc1611704","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Shrager","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2024.09.006_bib0665","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2024.09.006_bib0670","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1474-4422(18)30392-2","article-title":"Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial","volume":"18","author":"Wolfe","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2024.09.006_bib0675","doi-asserted-by":"crossref","first-page":"662856","DOI":"10.3389\/fneur.2021.662856","article-title":"Therapeutic plasma exchange in myasthenia gravis: a systematic literature review and meta-analysis of comparative evidence","volume":"12","author":"Ipe","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurol.2024.09.006_bib0680","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1001\/jama.291.19.2367","article-title":"Intravenous immunoglobulin in autoimmune neuromuscular diseases","volume":"291","author":"Dalakas","year":"2004","journal-title":"JAMA"},{"issue":"Suppl. 3","key":"10.1016\/j.neurol.2024.09.006_bib0685","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00415-008-3002-0","article-title":"Advances in the understanding of the mechanism of action of IVIg","volume":"255","author":"Hartung","year":"2008","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2024.09.006_bib0690","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/ncn3.12301","article-title":"Why is development of new treatments necessary for myasthenia gravis? Recent advances in clinical trials","volume":"7","author":"Imai","year":"2019","journal-title":"Neurol Clin Neurosc"},{"key":"10.1016\/j.neurol.2024.09.006_bib0695","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","article-title":"Rituximab: mechanism of action","volume":"47","author":"Weiner","year":"2010","journal-title":"Semin Hematol"},{"key":"10.1016\/j.neurol.2024.09.006_bib0700","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","article-title":"The regulation and function of CD20: an \u201cenigma\u201d of B-cell biology and targeted therapy","volume":"105","author":"Pavlasova","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.neurol.2024.09.006_bib0705","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00415-014-7532-3","article-title":"Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis","volume":"262","author":"Iorio","year":"2015","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2024.09.006_bib0710","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/nyas.14195","article-title":"Myasthenia gravis and specific immunotherapy: monoclonal antibodies","volume":"1452","author":"Cai","year":"2019","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.neurol.2024.09.006_bib0715","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.3390\/jcm11061597","article-title":"Current treatment of myasthenia gravis","volume":"11","author":"Alhaidar","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.neurol.2024.09.006_bib0720","doi-asserted-by":"crossref","first-page":"e2368","DOI":"10.1212\/WNL.0000000000200288","article-title":"Rituximab therapy in the treatment of juvenile myasthenia gravis: the French experience","volume":"98","author":"Molimard","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.09.006_bib0725","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/jamaneurol.2020.0851","article-title":"Comparison between rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis","volume":"77","author":"Brauner","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2024.09.006_bib0730","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","article-title":"Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial","volume":"79","author":"Piehl","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2024.09.006_bib0735","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1212\/WNL.0000000000013121","article-title":"Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: the BeatMG Study","volume":"98","author":"Nowak","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2024.09.006_bib0740","unstructured":"NCT04524273. Study Details | Myasthenia Gravis Inebilizumab Trial | ClinicalTrials. gov. ClinicaltrialsGov n.d. Available from: https:\/\/clinicaltrials. gov\/study\/NCT04524273."},{"key":"10.1016\/j.neurol.2024.09.006_bib0745","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2024.09.006_bib0750","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nrrheum.2009.184","article-title":"CD19: a promising B cell target for rheumatoid arthritis","volume":"5","author":"Tedder","year":"2009","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.neurol.2024.09.006_bib0755","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3389\/fimmu.2020.00917","article-title":"Complement inhibitor therapy for myasthenia gravis","volume":"11","author":"Albazli","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurol.2024.09.006_bib0760","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2024.09.006_bib0765","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1007\/s11136-019-02148-2","article-title":"Eculizumab improves fatigue in refractory generalized myasthenia gravis","volume":"28","author":"Andersen","year":"2019","journal-title":"Qual Life Res"},{"key":"10.1016\/j.neurol.2024.09.006_bib0770","first-page":"1","article-title":"Terminal complement inhibitor ravulizumab in generalized myasthenia gravis","author":"Vu","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.neurol.2024.09.006_bib0775","unstructured":"Ultomiris approvement web page. Ultomiris approved in the US for adults with generalised myasthenia gravis n.d. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2022\/ultomiris-approved-in-the-us-for-adults-with-generalised-myasthenia-gravis.html#."},{"key":"10.1016\/j.neurol.2024.09.006_bib0780","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1007\/s00415-023-11699-x","article-title":"Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase\u00a03 CHAMPION MG open-label extension","volume":"270","author":"Meisel","year":"2023","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2024.09.006_bib0785","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41573-019-0031-6","article-title":"Clinical promise of next-generation complement therapeutics","volume":"18","author":"Mastellos","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.neurol.2024.09.006_bib0790","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00439-004-1102-1","article-title":"A new locus for autosomal dominant Charcot-Marie-Tooth disease type 2 (CMT2L) maps to chromosome 12q24","volume":"114","author":"Tang","year":"2004","journal-title":"Hum Genet"},{"key":"10.1016\/j.neurol.2024.09.006_bib0795","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"Howard","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2024.09.006_bib0800","unstructured":"Zilucoplan received orphan drug desigantion web page. Ra Pharmaceuticals Receives Orphan Drug Designation from the U. S. FDA for zilucoplan for the treatment of myasthenia gravis | business wire n.d. https:\/\/www. businesswire.com\/news\/home\/20190904005284\/en\/Ra- Pharmaceuticals-Receives-Orphan-Drug-Designation-from-the-U.S.- FDA-for-Zilucoplan-for-the-Treatment-of-Myasthenia-Gravis."},{"key":"10.1016\/j.neurol.2024.09.006_bib0805","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/14712598.2023.2185131","article-title":"Ravulizumab for the treatment of myasthenia gravis","volume":"23","author":"Vanoli","year":"2023","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.neurol.2024.09.006_bib0810","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1172\/JCI106279","article-title":"Metabolic properties of IgG subclasses in man","volume":"49","author":"Morell","year":"1970","journal-title":"J Clin Invest"},{"key":"10.1016\/j.neurol.2024.09.006_bib0815","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41577-022-00821-1","article-title":"The therapeutic age of the neonatal Fc receptor","volume":"23","author":"Pyzik","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.neurol.2024.09.006_bib0820","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2024.09.006_bib0825","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.clinph.2020.09.001","article-title":"Electrophysiological testing in chronic inflammatory demyelinating polyneuropathy patients treated with subcutaneous immunoglobulin: the Polyneuropathy and Treatment with Hizentra (PATH) study","volume":"132","author":"Bril","year":"2021","journal-title":"Clin Neurophysiol"},{"key":"10.1016\/j.neurol.2024.09.006_bib0830","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan1208","article-title":"The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study","volume":"9","author":"Kiessling","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.neurol.2024.09.006_bib0835","doi-asserted-by":"crossref","first-page":"16011","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.neurol.2024.09.006_bib0840","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2024.09.006_bib0845","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaneurol.2016.0113","article-title":"Myasthenia gravis treated with autologous hematopoietic stem cell transplantation","volume":"73","author":"Bryant","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2024.09.006_bib0850","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/14728214.2021.1952982","article-title":"Emerging drugs for the treatment of myasthenia gravis","volume":"26","author":"Menon","year":"2021","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.neurol.2024.09.006_bib0855","doi-asserted-by":"crossref","first-page":"6394","DOI":"10.3390\/jcm11216394","article-title":"New targeted agents in myasthenia gravis and future therapeutic strategies","volume":"11","author":"S\u00e1nchez-Tejerina","year":"2022","journal-title":"JCM"},{"key":"10.1016\/j.neurol.2024.09.006_bib0860","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.nmd.2017.03.007","article-title":"Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab","volume":"27","author":"Jonsson","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.neurol.2024.09.006_bib0865","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jaut.2005.01.013","article-title":"Myasthenia gravis patients with low plasma IL-6 and IFN-gamma benefit from etanercept treatment","volume":"24","author":"T\u00fcz\u00fcn","year":"2005","journal-title":"J Autoimmun"},{"key":"10.1016\/j.neurol.2024.09.006_bib0870","unstructured":"NCT05067348. efficacy and safety of Tocilizumab in the treatment of generalized myasthenia gravis n.d. https:\/\/clinicaltrials.gov\/study\/NCT05067348."},{"key":"10.1016\/j.neurol.2024.09.006_bib0875","doi-asserted-by":"crossref","DOI":"10.1007\/s13760-024-02552-7","article-title":"Recommendations for the management of myasthenia gravis in Belgium","author":"De Bleecker","year":"2024","journal-title":"Acta Neurol Belg"},{"key":"10.1016\/j.neurol.2024.09.006_bib0880","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","article-title":"Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review","volume":"89","author":"Hehir","year":"2017","journal-title":"Neurology"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378724005988?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378724005988?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T17:36:14Z","timestamp":1730396174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378724005988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":88,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0035378724005988"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2024.09.006","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New treatment strategies in Myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2024.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}